Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Terlipressin
Drug ID BADD_D02167
Description Terlipressin is an analogue of vasopressin used as a vasoactive drug in the management of hypotension which has been found to be effective when norepinephrine fails.
Indications and Usage Commonly used to stop bleeding of varices in the food pipe (oesophagus).
Marketing Status approved; investigational
ATC Code H01BA04
DrugBank ID DB02638
KEGG ID D06672
MeSH ID D000077585
PubChem ID 72081
TTD Drug ID D0P4VX
NDC Product Code 41701-009; 41701-016; 43825-200
UNII 7Z5X49W53P
Synonyms Terlipressin | Glycylpressin | TGLVP | Terlypressin | Triglycyl Lysine Vasopressin | Triglycylvasopressin | Glipressin | Glypressin | Triglycyl-(8-lysine)vasopressin | Gly-Gly-Gly-8-Lys-vasopressin | Gly Gly Gly 8 Lys vasopressin | N-(alpha)-glycyl-glycyl-glycyl-8-lysine vasopressin | Vasopressin, tri-Gly-8-Lys- | tri-Gly-8-Lys- Vasopressin | Remestyp
Chemical Information
Molecular Formula C52H74N16O15S2
CAS Registry Number 14636-12-5
SMILES C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N) CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Atrial fibrillation02.03.03.002--
Blood creatinine decreased13.13.01.003---
Bradycardia02.03.02.002---
Cardiac failure02.05.01.001--
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.003---
Cyanosis02.11.04.004; 22.02.02.007; 23.06.04.005; 24.03.01.007--
Diarrhoea07.02.01.001--
Dyspnoea02.11.05.003; 22.02.01.004--
Gastrointestinal disorder07.11.01.001---
Headache17.14.01.001--
Hypertension24.08.02.001--
Hypervolaemia02.05.04.019; 14.05.06.003---
Hyponatraemia14.05.04.002--
Injection site necrosis08.02.03.020; 12.07.03.020---
Intestinal ischaemia07.15.02.001; 24.04.08.001---
Menopausal symptoms21.02.02.002---
Mesenteric vascular insufficiency07.15.02.010; 24.04.08.011---
Myocardial infarction02.02.02.007; 24.04.04.009--
Nausea07.01.07.001--
Nervous system disorder17.02.10.001---
Pallor08.01.03.032; 23.03.03.031; 24.03.04.001---
Peripheral ischaemia24.04.03.002--
Pregnancy18.08.02.004---
Pulmonary oedema02.05.02.003; 22.01.03.003--
Respiratory distress22.02.01.012---
Respiratory failure14.01.04.003; 22.02.06.002--
Skin disorder23.03.03.007---
Skin exfoliation23.03.07.003---
Skin necrosis23.03.03.011---
The 1th Page    1 2    Next   Last    Total 2 Pages